Klotho Neuro moves to acquire Turn Bio assets

Longevity biotech seeks to broaden its therapeutic capabilities with cellular reprogramming and delivery technologies. UPDATE: On October 7th, 2025, Klotho Neurosciences announced that its Letter of Intent to acquire assets from Turn Biotechnologies was allowed to expire. The company said its Board …